Knight Therapeutics (TSE:GUD) Rating Increased to Strong-Buy at Research Capitl

Research Capitl upgraded shares of Knight Therapeutics (TSE:GUD) from a hold rating to a strong-buy rating in a research note published on Tuesday morning,Zacks.com reports.

Separately, Raymond James upgraded shares of Knight Therapeutics to a “moderate buy” rating in a research report on Friday, November 15th. Two research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Knight Therapeutics currently has a consensus rating of “Strong Buy” and a consensus price target of C$7.08.

Knight Therapeutics Price Performance

GUD stock opened at C$5.88 on Tuesday. The firm’s 50-day moving average price is C$5.58 and its two-hundred day moving average price is C$5.56. Knight Therapeutics has a 12-month low of C$5.09 and a 12-month high of C$6.23. The stock has a market capitalization of C$594.76 million, a price-to-earnings ratio of -19.63, a PEG ratio of -1,013.50 and a beta of 0.50. The company has a current ratio of 3.36, a quick ratio of 1.79 and a debt-to-equity ratio of 7.52.

Insider Activity at Knight Therapeutics

In other Knight Therapeutics news, insider Sime Armoyan acquired 17,600 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The shares were acquired at an average price of C$5.48 per share, with a total value of C$96,488.48. 45.62% of the stock is owned by corporate insiders.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.